Day One Biopharmaceuticals, Inc., was incorporated in Delaware as a limited liability company in November 2018. As a commercial-stage biopharmaceutical company, the company focuses on the development of first-of-its-kind or best-in-class medicines for childhood and adult diseases. Day One adopts a search and development strategy to identify, acquire and advance drug programs, and its first commercialized product is tovorafenib, an oral, blood-brain barrier penetrating, highly selective type II RAF kinase inhibitor.
